Cronos Group

CRON on Nasdaq. Cronos Group sells cannabis products to consumers and patients in several countries. Market value $1.2bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
4.1%fair

For every $100 of what the whole company costs, it produced $4.12 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 48 of 100. Price score: 54 of 100. Our list needs 70 on quality and 60 on price.

$3.29 a share, 44% above its 1-year low

Over the past year the price has ranged from $2.28 to $3.61.

Dividend: 0.5% a year

Paid in its latest year

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.2
-0.1
-0.0
0.0
0.0
0.0
2021202220232024202512 monthsto Jun '26

Spare cash swings from quarter to quarter here: $50 million in the past 12 months, $149,000 in the year to December 2025.

Revenue
$65m$87m$87m$118m$147m
Operating margin
-452.2%-128.4%-97.2%-65.1%-11.9%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.38bn0.38bn0.38bn0.38bn0.37bn

Health checks

  • Free cash flow positive2 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)5 of 7 checks we could run
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsStrong, 25.7% a year
  • Buying back its own sharesYes, 3% fewer since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $53 million last quarter, up 58% on a year ago.
  • Profit: $32 million, after a loss of $40 million a year ago.
  • It loses 1 cents on each $1 of sales, compared with 42 cents a year earlier.
  • Spare cash over the past 12 months: $50 million. A year earlier it spent $9 million more than it brought in.
  • 3% fewer shares than a year ago. Each share owns a bit more of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$34m
December 2024$30m
March 2025$32m
June 2025$33m
September 2025$36m
December 2025$45m
March 2026$45m
June 2026$53m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024$8m
December 2024$44m
March 2025$6m
June 2025-$40m
September 2025$26m
December 2025-$2m
March 2026$14m
June 2026$32m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
26 February 2026
Next quarterly (estimated, 10-Q)
5 November 2026

Who owns it

2 long-term investors we follow own it, up from 1 last quarter. 194 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

No one has reported a stake above 5% since December 2024.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought or sold on the open market in the last 12 months.

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the serious warning signs we check for were found. 1 thing worth knowing.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Feb 2026, plus the 10-Q filed 6 Aug 2026 and 4 later 8-Ks.

  • One big customer

    Worth knowing

    One customer brings in a big share of sales: 27% last year. Losing that customer would hurt.

    “In 2025, there were two major customers, Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission, which accounted for approximately 27% and 16%, respectively, of the Company’s consolidated net revenues, before excises taxes, for the year ended December 31, 2025.”

    From the 10-K filed 26 February 2026, Item 1. Business. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.